Radiation protection assessment for interventional therapy with 90Y resin microspheres
GENG Jianhua1, CHEN Yingmao2, WANG Xiaotao3, LI Xueqin3
1. Department of Nuclear Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021 China; 2. Department of Nuclear Medicine, First Medical Center of Chinese PLA General Hospital, Beijing 100853 China; 3. Nuclear and Radiation Safety Center, Beijing 102442 China
[1] Burton MA, Gray BN, Klemp PF, et al. Selective internal radiation therapy: distribution of radiation in the liver[J]. Eur J Cancer Clin Oncol, 1989, 25(10): 1487-1491. DOI: 10.1016/0277-5379(89)90109-0 [2] van Hazel GA, Heinemann V, Sharma NK, et al. SIRFLOX: Randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer[J]. J Clin Oncol, 2016, 34(15): 1723-1731. DOI: 10.1200/JCO.2015.66.1181 [3] Chow PKH, Gandhi M, Tan SB, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma[J]. J Clin Oncol, 2018, 36(19): 1913-1921. DOI: 10.1200/JCO.2017.76.0892 [4] Takahashi A, Himuro K, Baba S, et al. Comparison of TOF-PET and bremsstrahlung SPECT images of yttrium-90: a Monte Carlo simulation study[J]. Asia Ocean J Nucl Med Biol, 2018, 6(1): 24-31. DOI: 10.22038/aojnmb.2017.9673 [5] Tafti BA, Padia SA. Dosimetry of Y-90 microspheres utilizing Tc-99m SPECT and Y-90 PET[J]. Semin Nucl Med, 2019, 49(3): 211-217. DOI: 10.1053/j.semnuclmed.2019.01.005 [6] 中华人民共和国国家卫生健康委员会. GBZ 128—2019 职业性外照射个人监测规范[S]. 北京: 中国标准出版社, 2019. National Health Commission of the People's Republic of China.GBZ 128—2019 Specifications for individual monitoring of occupational external exposure[S]. Beijing: Standards Press of China, 2019. [7] 中华人民共和国国家卫生健康委员会. GBZ 120—2020 核医学放射防护要求[S]. 北京: 中国标准出版社, 2020. National Health Commission of the People’s Republic of China. GBZ 120—2020 Requirements for radiological protection in nuclear medicine[S]. Beijing: Standards Press of China, 2020. [8] 中华人民共和国国家质量监督检验检疫总局. GB 18871—2002 电离辐射防护与辐射源安全基本标准[S]. 北京: 中国标准出版社, 2003. General Administration of Quality Supervision, Inspection and Quarantine of the People's Republic of China. GB 18871—2002 Basic standards for protection against ionizing radiation and for the safety of radiation sources[S]. Beijing: Standards Press of China, 2003. [9] Drescher R, Kühnel C, Seifert P, et al. Renal and intestinal excretion of 90Y and 166Ho after transarterial radioembolization of liver tumors[J]. AJR Am J Roentgenol, 2020, 214(5): 1158-1164. DOI: 10.2214/AJR.19.22049 [10] Lambert B, Sturm E, Mertens J, et al. Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital[J]. Eur J Nucl Med Mol Imaging, 2011, 38(12): 2117-2124. DOI: 10.1007/s00259-011-1881-2 [11] Grosser OS, Ruf J, Pethe A, et al. Urinary excretion of yttrium-90 after radioembolization with yttrium-90-labeled resin-based microspheres[J]. Health Phys, 2018, 114(1): 58-63. DOI: 10.1097/HP.0000000000000734 [12] 潘自强. 辐射安全手册[M]. 北京: 科学出版社, 2011: 39. Pan ZQ. Radiation safety manual [M]. Beijing: Science Press, 2011: 39. [13] Gulec SA, Siegel JA. Posttherapy radiation safety considerations in radiomicrosphere treatment with 90Y-microspheres[J]. J Nucl Med, 2007, 48(12): 2080-2086. DOI: 10.2967/jnumed.107.045443 [14] McCann JW, Larkin AM, Martino LJ, et al. Radiation emission from patients treated with selective hepatic radioembolization using yttrium-90 microspheres: are contact restrictions necessary[J]. J Vasc Interv Radiol, 2012, 23(5): 661-667. DOI: 10.1016/j.jvir.2012.01.070 [15] Kim YC, Kim YH, Uhm SH, et al. Radiation safety issues in y-90 microsphere selective hepatic radioembolization therapy: possible radiation exposure from the patients[J]. Nucl Med Mol Imaging, 2010, 44(4): 252-260. DOI: 10.1007/s13139-010-0047-7.[PubMed [16] International Atomic Energy Agency. IAEA Safety Reports Series No. 63Release of Patients After Radionuclide Therapy[S]. Vienna: IAEA, 2009. [17] International commission on Radiological Protection. ICRP Publication 94 Release of patients after therapy with unsealed radionuclides[M]. Elsevier:ICRP, 2004. [18] 中华人民共和国国家卫生和计划生育委员会. WS 533—2017 临床核医学患者防护要求[S]. 北京: 中国标准出版社, 2017. National Health and Family Planning Commission. WS 533—2017 Requirements for patient radiation protection in clinical nuclear medicine[S]. Beijing: Standards Press of China, 2017. [19] 中华人民共和国生态环境部. HJ 1188—2021 核医学辐射防护与安全要求[S]. 北京: 中国环境科学出版社, 2021. Ministry of Ecological Environment of the People’s Republic of China. HJ 1188—2021 Radiation protection and safety requirements for nuclear medicine[S]. Beijing: China Environment Science Press, 2021. [20] Metyko J, Williford JM, Erwin W, et al. Long-lived impurities of 90Y-labeled microspheres, TheraSphere and SIR-spheres, and the impact on patient dose and waste management[J]. Health Phys, 2012, 103(5 Suppl 3): S204-S208. DOI: 10.1097/HP.0b013e31826566f0
